Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart’s Top Stock Pick. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Innate Pharma S.A. ADR (IPHA)

Innate Pharma S.A. ADR (IPHA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 178,593
  • Shares Outstanding, K 79,729
  • Annual Sales, $ 29,230 K
  • Annual Income, $ -62,480 K
  • 60-Month Beta 0.85
  • Price/Sales 6.06
  • Price/Cash Flow N/A
  • Price/Book 1.43
Trade IPHA with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.00 +10.50%
on 11/03/22
2.53 -12.65%
on 11/14/22
+0.06 (+2.79%)
since 10/28/22
3-Month
1.92 +15.10%
on 10/03/22
3.16 -30.06%
on 09/21/22
-0.45 (-16.92%)
since 08/29/22
52-Week
1.92 +15.10%
on 10/03/22
5.38 -58.92%
on 12/17/21
-2.59 (-53.96%)
since 11/26/21

Most Recent Stories

More News
Innate Pharma Reports Third Quarter Financial Results

Regulatory News:

IPHA : 2.21 (-1.34%)
Innate Pharma Announces Conference Call and Webcast for Third Quarter 2022 Business Update

Regulatory News:

IPHA : 2.21 (-1.34%)
Innate Pharma to Present Results From a Preliminary Analysis of the TELLOMAK Phase 2 Trial in Patients With Advanced Sezary Syndrome and ANKET™ Platform at ASH 2022

Regulatory News:

IPHA : 2.21 (-1.34%)
Innate Pharma to Participate in Upcoming Investor Conferences

Regulatory News:

IPHA : 2.21 (-1.34%)
Innate Pharma 2023 Financial Calendar

Regulatory News:

IPHA : 2.21 (-1.34%)
Innate Pharma Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Mycosis Fungoides

Regulatory News:

IPHA : 2.21 (-1.34%)
Pre-Market Brief: Stocks Plunge As Fed Meeting Takes Centre Stage

December S&P 500 futures (ESZ22) are down -0.87% this morning after three major US benchmark indices recorded their greatest weekly losses in 3 months, with investors remaining cautious amid the economic...

ESZ22 : 3,967.50 (+0.14%)
TFI.FP : 7.200 (+1.34%)
VOW.D.DX : 181.475 (+0.40%)
MARA : 5.89 (-1.51%)
HUT : 1.1100 (unch)
RIOT : 4.24 (-0.24%)
COIN : 43.11 (+1.41%)
MSTR : 182.00 (+3.02%)
BLUE : 7.65 (+3.80%)
FIS : 67.53 (+3.05%)
IPHA : 2.21 (-1.34%)
VNTR : 0.6948 (-2.14%)
Innate Pharma Reports First Half 2022 Financial Results and Business Update

Regulatory News:

IPHA : 2.21 (-1.34%)
Innate Pharma Announces Conference Call and Webcast for First Half 2022 Business Update

Regulatory News:

IPHA : 2.21 (-1.34%)
Innate Pharma to Present Lacutamab PTCL Phase 1b Design and ANKET™ Platform at ESMO 2022

Regulatory News:

IPHA : 2.21 (-1.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Innate Pharma S.A. is a commercial stage oncology-focused biotech company. It discovers and develops therapeutic antibodies for the treatment of cancer. The company's commercial-stage product includes Lumoxiti. Innate Pharma S.A. is based in Marseille, France.

See More

Key Turning Points

3rd Resistance Point 2.29
2nd Resistance Point 2.28
1st Resistance Point 2.24
Last Price 2.21
1st Support Level 2.19
2nd Support Level 2.18
3rd Support Level 2.14

See More

52-Week High 5.38
Fibonacci 61.8% 4.06
Fibonacci 50% 3.65
Fibonacci 38.2% 3.24
Last Price 2.21
52-Week Low 1.92

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar